Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Key Therapeutic System for Reversing MAFLD-related Cirrhosis: a Randomized Double-blind Controlled Trial on the Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis

NCT06773221 is registered in ClinicalTrials.gov with Beijing Friendship Hospital as lead sponsor.

NCT NCT06773221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06773221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Key Therapeutic System for Reversing MAFLD-related Cirrhosis: a Randomized Double-blind Controlled Trial on the Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis
Lead sponsor
Beijing Friendship Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
February 5, 2025
Completion date
June 30, 2028
Enrollment
195 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

compensated liver cirrhosis, metabolic dysfunction associated fatty liver disease